Psylocybin - what is this substance?

How does psilocybin affect the brain?

Psilocybin is a naturally occurring psychedelic compound found in certain mushroom species. After ingestion it is converted in the body to psilocin, which interacts primarily with serotonin receptors in the brain, especially 5-HT2A. This can lead to intense changes in perception, emotion and sense of self — including visual phenomena, altered thinking and a feeling of expanded or disrupted consciousness. For a broader scientific overview, see psilocybin on Wikipedia.

In recent years interest in psilocybin has increased due to clinical trials exploring its potential in strictly controlled medical settings. Early studies suggest that, when combined with psychotherapy, it may help some people with treatment-resistant depression, certain anxiety disorders or addiction. These are experimental therapies conducted under rigorous supervision; they are not the same as unsupervised or recreational use. You can read more about safety aspects in our article are psilocybin mushrooms safe.

Although many participants in clinical trials report meaningful psychological insights, a sense of connection or spiritual experiences, psilocybin is not a universal cure and its long-term effects are still being studied. The same mechanisms that may support therapeutic change can also, in the wrong context, lead to anxiety, confusion or difficult emotional reactions — which is why set, setting and professional support are considered crucial in research environments.

Psilocybin versus psilocin – what is the difference?

Psilocybin and psilocin are closely related compounds found in so-called “magic mushrooms,” such as the popular research strain Golden Teacher. Psilocybin itself is a prodrug: after ingestion it is metabolised into psilocin, which then interacts with serotonin receptors and is responsible for most of the psychoactive effects.

Because psilocybin is more chemically stable than psilocin, it is easier to store and handle in laboratory conditions. Psilocin, by contrast, is the active molecule with a more direct effect on the central nervous system. In practice, both are part of the same pharmacological “chain,” and modern research usually focuses on psilocybin as the compound administered in controlled clinical studies.

Does psilocybin cure depression?

Psilocybin has become a major focus of research into new approaches for treatment-resistant depression. Several clinical trials led by institutions such as Johns Hopkins University and Imperial College London have shown that, in carefully controlled settings and in combination with psychotherapy, psilocybin sessions can significantly reduce depressive symptoms in some patients.

In one well-known trial at Johns Hopkins, participants with major depressive disorder received a small number of supervised psilocybin sessions alongside structured psychological support. Many experienced a substantial reduction in depression scores, and some improvements persisted for weeks or months. Similar results have been reported in other early-stage studies, suggesting that psilocybin-assisted therapy could become a valuable option in the future for selected patients who do not respond to standard treatments.

However, it is important to underline that these are still relatively small studies, and psilocybin remains a controlled substance in many countries. Therapy involving psilocybin is not widely available, and outside of approved clinical trials or highly regulated programmes, its use is usually illegal. Anyone considering participation in such research should always rely on official information from recognised medical centres and never attempt to self-medicate.

Is psilocybin legal?

Legal regulations around psilocybin differ widely between countries and are changing over time. We describe this in more detail in our article where psilocybin mushrooms are legal, but the general picture is still restrictive in most jurisdictions.

In the United States, psilocybin is currently listed as a Schedule I substance under federal law, which means it is officially considered to have “no accepted medical use” and a high potential for abuse. Some cities and states have begun to explore decriminalisation or create tightly controlled therapeutic frameworks, but these remain exceptions.

In Europe, psilocybin is generally illegal, although details differ between countries. In the Netherlands, for example, certain psilocybin-containing truffles can be sold under specific regulations, while dried mushrooms remain banned. In Poland, psilocybin is classified as an illegal drug and its possession, distribution or use can lead to criminal charges.

Golden Teacher mushrooms, and other psilocybin-containing varieties, therefore remain illegal to cultivate, possess or consume in many parts of the world. At the same time, more countries are allowing or planning clinical research, which may gradually change medical frameworks — but this does not translate into general legalisation for individual use.

How is psilocybin dosed in research?

In clinical studies, psilocybin is administered in carefully controlled doses that are matched to the individual and monitored by medical staff. Factors such as body weight, current medication, mental and physical health and previous psychiatric history are taken into account. Dosing takes place in a hospital or specialised clinic, with continuous supervision and a clear emergency protocol.

Because responses to psilocybin can vary widely between individuals, copying research doses outside of a clinical context is both unsafe and illegal in many countries. Self-experimenting with “light” or “medium” doses carries a risk of intense psychological reactions, panic, confusion or the exacerbation of hidden mental health problems. For these reasons, serious organisations emphasise that psilocybin should only be used within properly regulated studies or approved medical programmes — not as a casual self-help tool.

Psilocybin and “Industry 4.0” – myths and speculations

Commentary about “psilocybin in Industry 4.0” sometimes appears in popular media, often in the context of creative work, innovation or artificial intelligence. These narratives usually focus on anecdotal accounts from entrepreneurs or creatives who claim that psychedelic experiences helped them look at problems from a new perspective or notice unexpected patterns.

From a scientific standpoint, it is true that psilocybin can temporarily change how the brain organises information and connects different networks. Functional imaging studies show altered patterns of activity and connectivity during a psychedelic experience. Some authors speculate that this might inspire new ideas for algorithms or design — but this is more a metaphorical inspiration than a direct “tool” for machine learning.

In practical terms, real progress in Industry 4.0 and AI still comes primarily from mathematics, engineering, data and interdisciplinary collaboration, not from substance use. Treating psilocybin as a shortcut to innovation is risky and ignores the legal and health consequences described above.

Why consultation with a doctor and therapist is essential

Like any powerful psychoactive substance, psilocybin can have unpredictable and sometimes dangerous effects. Before participating in any psychedelic-assisted therapy or research, it is crucial to consult with qualified medical professionals. A doctor can assess general health, possible contraindications and interactions with medications, while a therapist can prepare the psychological framework and help integrate any experiences.

This is particularly important for people with mental health conditions such as depression, anxiety disorders, bipolar disorder or past psychosis. For some individuals, psilocybin may increase psychological risk, and in such cases participation in psychedelic sessions may be contraindicated, even in a clinical setting.

It is also important to remember that psilocybin itself is not therapy. At best, it is a tool that may support a broader therapeutic process when used in a safe, structured, professionally guided context. Without preparation, integration and a stable environment, even seemingly “positive” experiences can be confusing or destabilising.

When psilocybin is not recommended

Despite promising research results, there are clear situations in which psilocybin is considered high-risk or inappropriate. These include, for example:

People with certain mental illnesses

Individuals with a history of psychosis, schizophrenia, schizoaffective disorder or some forms of bipolar disorder are often excluded from clinical trials. In such cases psilocybin may intensify symptoms or trigger a relapse, which is why researchers and clinicians typically exercise extreme caution.

Pregnancy and breastfeeding

There is a lack of solid data on the safety of psilocybin use during pregnancy or lactation. For ethical and medical reasons, clinical studies generally exclude pregnant and breastfeeding people, and use of psilocybin in these periods is not recommended.

Cardiovascular disease

Psilocybin can cause temporary changes in blood pressure and heart rate. For people with significant cardiovascular disease (e.g. uncontrolled hypertension, severe coronary disease, serious arrhythmias or heart failure) this may pose additional risk. In research, such patients are often excluded or monitored very closely.

Severe anxiety disorders or instability

Psilocybin sessions can be emotionally intense and sometimes bring up difficult material from the past. For people with severe anxiety disorders, panic attacks or unstable functioning, this may be overwhelming. Thorough screening and careful risk–benefit assessment by professionals are essential.

Whenever there is doubt, the safest course of action is to talk to a doctor or therapist rather than make decisions based on internet stories or marketing narratives.

A few words about psilocybin in conclusion

In summary, psilocybin — the hallmark compound of so-called “magic mushrooms” — is a powerful psychedelic alkaloid that acts on serotonin receptors in the brain. Modern clinical studies suggest that, within structured therapeutic frameworks, it may help some people with depression, anxiety or addiction. At the same time, psilocybin mushrooms remain illegal to cultivate, possess or consume in many countries, including Poland. Even varieties popular in research culture, such as Golden Teacher, are subject to strict legal restrictions when grown for psychoactive use.

More and more scientific centres are conducting legitimate clinical trials, and public discussion about the therapeutic potential of psychedelics is becoming richer and more nuanced. Nevertheless, caution, critical thinking and respect for the law remain essential. Anyone interested in this field is safest when following reliable sources, reading original research and avoiding self-experimentation.

The content on the psychodelicroom.pl website is educational and research-focused. We do not encourage the use of any substances that affect consciousness. All such substances can both heal and cause serious harm, depending on context, dose and individual vulnerability. In particular, we advise against cultivating mushrooms from growkits in countries where it is illegal – including Poland – because this may involve criminal liability. Growkits purchased from us are intended solely for research and collection purposes, and we recommend disposing of them within 72 hours of receiving them, in accordance with local law.